We focused on IFN-γ, which is FDA-approved to decrease the frequency and severity of infections in CGD (74), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage–colony stimulating factor (GM-CSF), which are FDA-approved to accelerate myeloid reconstitution following hematopoietic stem cell transplantation or myeloablative chemotherapy (75). The gene discussed is CSF3; the disease is chronic granulomatous disease.